- Home
- APLT vs VRCA Comparison
APLT vs VRCA Comparison
Compare APLT & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- VRCA
- Stock Information
- Founded
- APLT 2016
- VRCA 2013
- Country
- APLT United States
- VRCA United States
- Employees
- APLT N/A
- VRCA N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- APLT Health Care
- VRCA Health Care
- Exchange
- APLT Nasdaq
- VRCA Nasdaq
- Market Cap
- APLT 63.6M
- VRCA 58.7M
- IPO Year
- APLT 2019
- VRCA 2018
- Fundamental
- Price
- APLT $0.42
- VRCA $4.75
- Analyst Decision
- APLT Buy
- VRCA Hold
- Analyst Count
- APLT 6
- VRCA 5
- Target Price
- APLT $6.10
- VRCA $60.00
- AVG Volume (30 Days)
- APLT 883.6K
- VRCA 36.2K
- Earning Date
- APLT 11-06-2025
- VRCA 11-03-2025
- Dividend Yield
- APLT N/A
- VRCA N/A
- EPS Growth
- APLT N/A
- VRCA N/A
- EPS
- APLT N/A
- VRCA N/A
- Revenue
- APLT $121,000.00
- VRCA $14,704,000.00
- Revenue This Year
- APLT N/A
- VRCA $264.34
- Revenue Next Year
- APLT $5,931.24
- VRCA $33.95
- P/E Ratio
- APLT N/A
- VRCA N/A
- Revenue Growth
- APLT N/A
- VRCA 5.72
- 52 Week Low
- APLT $0.30
- VRCA $3.82
- 52 Week High
- APLT $10.62
- VRCA $20.60
- Technical
- Relative Strength Index (RSI)
- APLT 38.92
- VRCA 31.51
- Support Level
- APLT $0.43
- VRCA $4.87
- Resistance Level
- APLT $0.46
- VRCA $5.20
- Average True Range (ATR)
- APLT 0.03
- VRCA 0.36
- MACD
- APLT -0.01
- VRCA -0.04
- Stochastic Oscillator
- APLT 0.35
- VRCA 0.57
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.